S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer
A multicenter, randomized, open-label, phase III trial of S-1 plus cisplatin (3 weekly) versus S-1 plus oxaliplatin chemotherapy for the first-line treatment of advanced gastric cancer
Gastric Cancer
DRUG: S-1|DRUG: Cisplatin|DRUG: Oxaliplatin
Progression-free survival, The primary endpoint of this study is progression-free survival. This is defined as the time from randomization to disease progression or death due to any cause., From date of randomization to the date of first documented progression or date of death from any cause, whichever came first, assessed up to 3 years
Overall survival, Overall survival is defined as the time from randomization to death due to any cause., From date of randomization to death from any cause, assessed up to 3 years|Response rate, Response assessment will be performed according to Response Evaluation Criteria in Solid Tumors (RECIST) criteria version 1.1 every 2 cycles (6 weeks) of treatment., Every 6 weeks|Quality of life, Quality of life of patient will be evaluated using EUROQOL(EQ-5D). Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment., Every 6 weeks|Number of Adverse Events, Monitoring for safety and toxicity will be performed every cycle (3 weeks) of chemotherapy and whenever patients have problems., Every 3 weeks
A multicenter, randomized, open-label, phase III trial of S-1 plus cisplatin (3 weekly) versus S-1 plus oxaliplatin chemotherapy for the first-line treatment of advanced gastric cancer